Supreem Pharmaceuticals Mysore Profile
Key Indicators
- Authorised Capital ₹ 5.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 3.94 Cr
as on 24-10-2024
- Company Age 28 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 47.34 Cr
as on 24-10-2024
- Satisfied Charges ₹ 6.70 Cr
as on 24-10-2024
- Revenue 7.32%
(FY 2023)
- Profit -617.53%
(FY 2023)
- Ebitda -210.29%
(FY 2023)
- Net Worth -46.82%
(FY 2023)
- Total Assets 13.06%
(FY 2023)
About Supreem Pharmaceuticals Mysore
The Corporate was formerly known as Candor Laboratories Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.50 Cr and a paid-up capital of Rs 3.94 Cr.
The company currently has active open charges totaling ₹47.34 Cr. The company has closed loans amounting to ₹6.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sadanand Rao, Geetha Rao, Aditya Rao, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231KA1996PTC020988
- Company No.
020988
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Mysore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Supreem Pharmaceuticals Mysore Private Limited offer?
Supreem Pharmaceuticals Mysore Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Medical Laboratory Instruments, VTM Kit Raw Materials, Ayurvedic & Herbal Extracts, Herbal Extracts, Multivitamin Syrup & Drops, Vitamin D3 Drops, Pharma Ingredients & Raw Materials, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Supreem Pharmaceuticals Mysore?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sadanand Rao  | Managing Director | 16-Aug-1996 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amit Rao | Whole-Time Director | 10-Jul-2020 | Current |
| Geetha Rao | Whole-Time Director | 22-Jan-2008 | Current |
| Aditya Rao | Whole-Time Director | 10-Jul-2020 | Current |
Financial Performance of Supreem Pharmaceuticals Mysore.
Supreem Pharmaceuticals Mysore Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.32% increase. The company also saw a substantial fall in profitability, with a 617.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 46.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Supreem Pharmaceuticals Mysore?
In 2023, Supreem Pharmaceuticals Mysore had a promoter holding of 61.84% and a public holding of 38.16%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 11 Jul 2023 | ₹9.04 Cr | Open |
Karnataka State Financial Corporation Creation Date: 09 Oct 2013 | ₹8.30 Cr | Open |
State Bank Of India Creation Date: 21 Nov 2007 | ₹29.65 Cr | Open |
How Many Employees Work at Supreem Pharmaceuticals Mysore?
Supreem Pharmaceuticals Mysore has a workforce of 207 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Supreem Pharmaceuticals Mysore, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supreem Pharmaceuticals Mysore's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
